Insmed (INSM) hit a new 52-week high on Aug. 18, with a Weighted Alpha of +67.81 and a 100% “Buy” opinion from Barchart. The stock gained 64.02% over the past year and has a Trend Seeker “Buy” signal intact. Insmed is valued at $26.9 billion and is trading above its moving averages. Revenue is expected to grow 28.82% this year and 126.13% next year, with earnings also projected to increase.

Insmed is a biopharmaceutical company focused on developing ARIKAYCE for orphan patient populations with lung infections. The stock has seen impressive gains, making 15 new highs and rising 24.09% in the last month. Wall Street analysts have mixed opinions on INSM, with price targets ranging from $110-$240. CFRA’s MarketScope Advisor rates the stock a “Sell,” while Morningstar thinks it’s fairly valued.

Investors should be cautious with INSM’s volatility and speculative nature, using strict risk management and stop-loss strategies. Despite hitting new highs and having strong technical momentum, it is important to consider the wide range of analyst opinions and potential risks associated with the stock.

Read more at Yahoo Finance: This ‘Strong Buy’ Pharma Stock Is Surging to New Highs